Unlock instant, AI-driven research and patent intelligence for your innovation.

Target thrombolytic protein expressing plasmid and its construction

A technology for expressing plasmids and annexin, applied in the field of medicine and biology, can solve the problems of easy thrombosis, large amount of treatment, lack of specific affinity for fibrin, etc.

Inactive Publication Date: 2003-02-26
敏昌国际有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the commonly used clinical thrombolytic drugs are mainly plasminogen activators, such as streptokinase (SK), urokinase (UK), single-chain urokinase (scu-PA), tissue plasminogen activator (t -PA), etc., although these drugs have strong thrombolytic effect, there are many disadvantages: (1) bleeding: because these drugs not only activate the plasminogen in the fibrin clot, but also activate the plasminogen in the plasma Plasminogen, which increases the activity of plasmin in plasma
(2) The half-life in the body is short, and the therapeutic dosage is large
Therefore, thrombosis is easy to form again in a short time after thrombolysis, which makes the treatment fail.
[0003] Low-molecular-weight single-chain urokinase (scu-PA (144-411)) is a derivative of single-chain urokinase (scu-PA), composed of 144-411 amino acid residues of scu-PA, and its thrombolytic properties are similar to those of scu-PA. -PA is similar, with less bleeding side effects, but lacks specific affinity for fibrin, so the efficiency of thrombolysis is not high, and its clinical application is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Target thrombolytic protein expressing plasmid and its construction
  • Target thrombolytic protein expressing plasmid and its construction
  • Target thrombolytic protein expressing plasmid and its construction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1 The acquisition of fusion gene anx32-scu-PA (144~411)

[0032] See figure 1 , the gene encoding annexin 32 and the gene encoding amino acids 144-411 of single-chain urokinase were respectively amplified by PCR; then the fusion gene anx32-scu-PA(144-411) was obtained by connecting by overlapping region extension . Specific steps are as follows:

[0033] (1) The entire coding gene of annexin 32 gene was amplified with primer a and primer b. Wherein primer a is 5'TG GAATTC ATGGCCTACTGTCGCTCCC3', the primer is consistent with the 5' end of the anx32 coding sequence, and at the same time introduces the EcoRI restriction endonuclease site. Primer b is: 5'GCCACACTGAAATTTTAA / TGCAGGGCCGATGAG3', wherein 18 bp at the 5' end is consistent with the 5' end of the single-stranded urokinase coding sequence, and the latter 15 bp is complementary to the 3' end of the anx32 gene. PCR reactions were performed using high-fidelity pfu DNA polymerase with a dNTP concentrat...

Embodiment 2

[0036] Example 2 Construction of expression plasmid pJM-anx32-scuPA

[0037] The fusion gene anx32-scu-PA (144-411) amplified by the above method was sequenced using primers a and d, and the sequencing reaction was completed by Shanghai Jikang Company. After the sequencing was correct, it was digested with EcoRI and SalI, and connected with the vector pJM which was digested with EcoRI and SalI. Restriction enzymes and T for digestion and ligation reactions 4 All ligases were purchased from TaKaRa Company, and the reaction was carried out using the system recommended by the enzyme instructions. The heat-inducible expression vector pJM utilized in the present invention has a full length of 4.9Kb (kilobase pairs), containing phage P R P L Promoter, heat-inducible gene CI1857, plasmid origin of replication (ori) and ampicillin resistance gene (AP r ).

[0038] The specific reaction process is as follows: EcoRI and SalI were used to perform double enzyme digestion on the above...

Embodiment 3

[0039] The preparation of embodiment 3 engineering bacteria

[0040] The above ligated product was transformed into Escherichia coli strain K802 to obtain engineering strain K802 (pJM-anx32-scuPA).

[0041] The specific steps are as follows: in 50ml of LB medium (containing 1% tryptone, 0.5% yeast extract and 1% sodium chloride, pH7.0), the host bacterium K802 was shaken at 37°C until OD 600 At 0.4, centrifuge at 4000rpm at 4°C to collect the host bacteria; remove the supernatant and resuspend with 1-2ml of ice-cooled 100mmol / L calcium chloride solution to obtain competent bacteria. Cool 100 ng of the plasmid constructed above and competent bacteria in an ice bath for 30 minutes, heat shock at 42° C. for 90 seconds, and then cool in an ice bath for 10 minutes. Add 0.8ml of LB, incubate at 37°C for 1 hour, take 0.2ml of the transformation product and smear it on the LB agar plate containing the corresponding antibiotic, and incubate at 37°C for 12-15 hours to obtain a single-c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides a fusion gene anx32-scuPA of annexin 32 encoding gene and single-strand urokinase sites 144-411 amino acid encoding gene; its thermoinducible expression plasmid pJM-anx32-scuPA and 6.8 Kb(Kilobarn) long circular double strand; and engineering bacterium K802(pJM-anx32-scuPA) prepared with the plasmid converted colibacillus strain K802. The fusion gene of the present invention can express and fusion protein of annexin 32 and single-strand urokinase sites 144-411 amino acid (scu-PA(144-411)). The fusion protein has the functions of both anticoagulation and thrombolysis and has high thrombolytic efficiency and no breeding and other side effect.

Description

technical field [0001] The invention relates to the technical field of medicine and biology, in particular to the preparation of thrombus-targeted thrombolytic protein expression plasmid by genetic engineering method. Background technique [0002] Thrombosis, such as acute myocardial infarction (AMI) and venous thromboembolism, is a class of cardiovascular diseases that seriously endanger human health and life. In western countries, the death caused by thrombosis has accounted for the first place in the total death rate of the population. In my country, with economic development and population aging, the number of patients with thrombosis is increasing, and the demand for antithrombotic drugs is also increasing. At present, the commonly used clinical thrombolytic drugs are mainly plasminogen activators, such as streptokinase (SK), urokinase (UK), single-chain urokinase (scu-PA), tissue plasminogen activator (t -PA), etc., although these drugs have strong thrombolytic effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47C12N9/72
CPCC07K2319/00C07K14/4721C12N9/6462C12Y304/21073C07K2319/003
Inventor 孙树汉颜宏利陈蕊雯秦沪兴
Owner 敏昌国际有限公司